Sarepta Therapeutics, Inc. (SRPT) स्टॉक विश्लेषण

कंपनी का अवलोकन

Sarepta Therapeutics, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the discovery and development of RNA-targeted therapeutics, including its proprietary siRNA platform, gene therapy, and other genetic therapeutic modalities specifically designed for the treatment of rare diseases. The company functions within the healthcare sector and the biotechnology industry, a domain characterized by significant research and development expenditures and the potential for high-value treatments targeting unmet medical needs. As of the latest data, the company holds a market capitalization of $2.30B and generates annual revenue of $2.20B while employing a workforce of 835 individuals. These valuation and revenue figures indicate that Sarepta maintains a substantial market presence within the niche biotechnology space, reflecting its established pipeline and commercialization capabilities despite operating in a highly competitive and capital-intensive environment focused on genetic disorders.

वित्तीय स्वास्थ्य

The company reported revenue of $2.20B over the trailing twelve months, yet recorded a net income of $-713,409,984 and an EBITDA of $-613,251,008, revealing a cost structure where operational expenses significantly outweigh current revenue generation. Despite the negative net income, the company demonstrates a degree of financial flexibility by generating free cash flow of $95.92M, which suggests that capital expenditures are not fully eroding the cash generated from operations. The gross margin stands at -7.4%, the operating margin is -92.6%, and the profit margin is -32.5%; these negative figures indicate that the company is currently in a phase of heavy investment or commercial scaling where costs exceed revenues before achieving profitability. On the balance sheet, the company holds $939.65M in cash against $1.04B in debt, resulting in a debt-to-equity ratio of 91.14, which characterizes a leveraged financial position typical for biotechnology firms funding R&D and clinical trials. The current ratio of 2.32 indicates that the company possesses sufficient liquid assets to cover its short-term obligations more than twice over, providing a buffer against immediate liquidity pressures. Furthermore, the return on equity is -53.5% and the return on assets is -11.2%, metrics that reveal management is currently deploying capital to generate losses rather than returns, a common strategy in growth-stage biotechnology companies aiming to secure future market share.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is listed as N/A due to negative earnings, while the forward P/E is 7.20, implying that the market expects future earnings to turn positive or that valuation is being assessed on discounted cash flow and pipeline value rather than current profitability. The price-to-book ratio is 2.02, indicating that the market values the company at twice its book value, suggesting a premium assigned to its intangible assets such as intellectual property and clinical pipeline potential. Alternative valuation metrics show a price-to-sales ratio of 1.05 and an EV/EBITDA of -3.91, which suggests the market is pricing the stock based on revenue multiples and expected future cash flows rather than current earnings power. The stock has a 52-week high of $64.80 and a 52-week low of $10.42, placing the current trading price within a wide historical range that reflects high volatility and uncertainty regarding future clinical outcomes and commercial adoption. The beta value of 0.28 indicates that the stock's price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market movements but carries specific idiosyncratic risks associated with its development stage.

Growth & Income

Revenue growth year-over-year stands at -32.7%, while earnings growth is N/A due to negative earnings; this combination implies that the company is currently contracting in terms of top-line revenue while simultaneously managing substantial operating losses that prevent meaningful earnings expansion. As a non-dividend payer, Sarepta maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings and cash reserves back into research and development rather than distributing income to shareholders. The overall growth and income profile reflects a classic biotechnology trajectory where negative revenue growth in the short term is balanced against the strategic imperative to fund high-cost drug development programs and achieve long-term commercial viability in the rare disease market.